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INTRODUCTION
Atopic diseases, including atopic dermatitis (also known as 
eczema), allergic rhinitis and asthma, have increased in frequen-
cy in recent decades and now affect approximately 20% of the 
population in the developed countries. The concept of the atop-
ic march was developed to describe the progression of atopic 
disorders from atopic dermatitis (AD) in infants to allergic rhi-
nitis and asthma in children.
1 Patients with AD may develop a 
typical sequence of AD and allergic rhinitis and asthma, which 
develop at certain ages; some may persist for several years, 
whereas others may resolve with increasing age.
2 Atopy is de-
fined as a personal and/or familial propensity to produce IgE 
antibodies and sensitization in response to environmental trig-
gers.
3 Underlying atopy has been considered to be critical in 
linking AD, allergic rhinitis and asthma.
1,4 The risk of develop-
ing all atopic diseases is complex and the temporal pattern de-
scribed in the atopic march may not be a simple progression 
and the development of these diseases is strongly influenced by 
both genetic and environmental factors. These disorders, while 
sharing genetic and environmental risk factors, can be unrelat-
ed disorders that may develop sequentially along an atopic path-
way or there may be a causal link between eczema and these 
later-onset atopic respiratory disorders. However, the concept 
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of the atopic march has been supported by cross-sectional and 
longitudinal studies,
5-14 and is confirmed when examining data 
on the prevalence of each atopic disease across the lifespan as 
well as by experimental evidence of mouse models.
THE FIRST STEP OF THE ATOPIC MARCH: ATOPIC 
DERMATITIS
Many studies have referred specifically to AD, and in this re-
view the terms atopic dermatitis and eczema are considered in-
terchangeable. AD is a common chronic pruritic skin disease 
seen in infants and children. In the International Study of Asth-
ma and Allergies in Childhood (ISAAC), among the 56 coun-
tries, the prevalence of AD in children varied significantly from 
0.3% to 20.5% but shows consistent trends in increasing disease 
prevalence over time.
15,16 In a population based study in the US, 
the prevalence of AD among children 5 to 9 years old is estimat-
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ed at 17.2%.
17 AD starts early in the first few years in life. Of the 
affected children, 45% of them had the condition during the 
first 6 months of life, 60% during the first year of life and up to 
85% suffered AD before 5 years of age.
4,18 Less than half of the 
patients with AD have complete resolution by 7 years of age and 
only 60% of them have resolution by adulthood, indicating the 
chronic nature of AD.
1,4,19
AD is a major risk factor for the development of asthma, with 
an increased odds ratio in children with AD in several longitu-
dinal studies compared with children without AD. Patients with 
eczema with specific IgE antibodies to common environmental 
allergens (extrinsic AD), present by the age of 2 to 4 years, are at 
a higher risk for progressing in the atopic march to allergic rhi-
nitis and asthma than those with eczema without IgE sensitiza-
tion (intrinsic AD).
9,20 Thus, extrinsic AD appears to more pre-
cisely define the initial step and risk factor for the subsequent 
development of other atopic diseases. The main risk factors for 
progression and persistence of asthma are early onset, IgE sen-
sitization, and severity of AD. Approximate 70% of patients with 
severe AD develop asthma compared with 20-30% of patients 
with mild AD and approximately 8% in the general population. 
Only children with the mildest AD did not develop either asth-
ma or allergic rhinitis. Similarly the severity of AD correlated 
with the risk of developing rhinitis and with elevated levels of 
total and specific IgE antibodies.
8 Of note, an important aspect 
of the natural history of AD is the number and percentage of 
patients who will outgrow their disease.
5 The mechanisms of 
the “outgrow” of AD remain largely unknown and this could be 
influenced by both genetic and environmental factors.
THE END POINTS (PROGRESSION) OF THE ATOPIC 
MARCH: ALLERGIC RHINITIS AND ASTHMA
The atopic march is supported by many cross-sectional and 
longitudinal studies highlighting AD as a possible first step of 
this process. van der Hulst et al.
12 examined the risk of develop-
ing asthma in young children with extrinsic AD from 13 pro-
spective cohort studies including 4 representing birth cohort 
studies and 9 representing eczema cohort studies. In the birth 
cohort studies, the odds ratio for the risk of asthma in subjects 
with AD, compared with children without AD was 2.14. The 
prevalence of asthma at the age of 6 years in AD cohort studies 
was about 30%. There was an increased risk of developing asth-
ma after AD in early childhood and 1 in every 3 children with 
eczema developed asthma during later childhood. Kapoor et 
al.
13 examined the prevalence of allergic rhinitis and asthma in 
2,270 children with physician-confirmed AD and found that by 
3 years of age, nearly 66% of the subjects reported to have aller-
gic rhinitis or asthma or both and the presence of these diseas-
es correlates with poor AD control. The Tucson Children’s Re-
spiratory Study found that eczema during the first year of life is 
an independent risk factor for persistent wheezing and 18% of 
children with wheezing at 6 years of age had eczema before 2 
years of age.
6,21 The cohort study followed the subjects who 
reached 22 years of age and fund that childhood asthma is 
strongly associated with eczema, whereas adult-onset asthma 
is not.
20 A prospective study examined development of allergies 
and asthma in infants with AD, follow-up to 7 years of age, 
showed that the eczema improved in 82 of the 94 children, but 
43% developed asthma and 45% allergic rhinitis.
8 The risk of de-
veloping asthma was higher in children with eczema, and an 
early onset of eczema was associated with an increased risk of 
sensitization to inhalant allergens. The studies indicate that IgE 
sensitization to environmental allergens in patients with ecze-
ma is an important contributing factor to progression into an 
allergic phenotype of asthma. In a German Multicenter Atopy 
Study, 1,314 newborns were recruited and analyzed and in this 
group, 499 infants were at increased risk of atopic disease. Their 
results showed that disease severity and atopic sensitization are 
major determinants of increased risk of subsequent wheeze or 
bronchial hyperreactivity; in contrast, early AD without these 
cofactors constituted no increased risk of subsequent wheeze.
22 
The Tasmanian Longitudinal Health Study investigated the in-
fluence of eczema on the development of asthma from child-
hood to adult life and found that childhood eczema was signifi-
cantly associated with new-onset asthma in three separate life 
stages: pre-adolescence (hazard ratio 1.70; 95% confidence in-
terval [CI] 1.05–2.75), adolescence (2.14; 1.33–3.46), and adult 
life (1.63; 1.28–2.09) as well as over the life-span from the ages 
of 8 to 44 years (1.73; 1.42–2.12).
23 This study strongly suggests 
that the atopic march progresses well past childhood. It is still 
unclear why some of the infants with AD outgrow the disease 
with increasing age, whereas others will “march” to develop 
other atopic conditions such as allergic rhinitis and/or asthma 
in later stages.
Epidemiologic studies have consistently demonstrated strong 
associations between rhinitis and asthma.
24-28 Recent clinical 
and basic science evidence indicated that the two diseases share 
anatomical, physiological, immunopathological, and therapeu-
tical factors.
29 Allergic rhinitis is an inflammatory condition af-
fecting nasal mucosal membranes. In sensitized individuals, al-
lergens such as pollens, molds, and animal dander provoke this 
allergic response. Although allergic rhinitis is often trivialized, it 
has a significant impact on quality of life and substantial socio-
economic consequences, and it is associated with multiple co-
morbidities, including asthma. Cardinal features of asthma in-
clude airway inflammation and airway hyperreactivity to aller-
gens associated with structural remodeling. Studies on the 
prevalence of asthma in patients with rhinitis varies consider-
ably, but has been reported to be as high as 80%.
29 Many pa-
tients with allergic rhinitis have lower airway hyperreactivity or 
bronchial hyperresponsiveness. Allergic rhinitis as a risk factor 
for developing asthma has been supported by several stud-
ies.
4,30 Ciprandi et al.
30 showed that nasal symptoms, airflow Atopic Dermatitis: First Step in the Atopic March AAIR 
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and markers of inflammation (eosinophils, Th2 cytokine levels) 
directly correlated with lower airway markers including forced 
expiratory volume in 1 second (FEV1). Leynaert et al.
24 found 
that approximate 75% of subjects with asthma reported rhinitis; 
patients with rhinitis have increased risk for asthma and lower 
airway reactivity compared with patients without rhinitis; and 
the risk for asthma increased from 2.0% in subjects without rhi-
nitis to 18.8% in subjects with allergic rhinitis either when ex-
posed to pollen or to animal dander. These studies suggested 
that allergic rhinitis is considered as a risk factor for asthma and 
can precede asthma in the atopic march.
ROLE OF FOOD ALLERGY IN THE ATOPIC MARCH
Over the past decade, a significant increase in the prevalence 
of food allergy-related anaphylaxis
31,32 indicates that there is a 
rise in food allergy. AD and food allergy commonly co-exist, par-
ticularly in those with early onset, severe and persistent atopic 
eczema. Food allergy is a known provoking cause of AD and the 
prevalence of IgE-mediated food allergy among children with 
AD is about 35% of affected children.
33 Whether children with 
IgE-mediated food allergy are at increased risk of developing 
subsequent other allergic manifestations (asthma and allergic 
rhinitis) is unclear. In a most recent study, investigators prospec-
tively followed 118 children with cow’s milk allergy (CMA) at 
baseline and assessed whether challenge-proven CMA in in-
fancy predisposes children to bronchial hyperresponsiveness 
at school age. They found that children with a history of IgE-
positive CMA diagnosed at a mean age of 7 months, not IgE-
negative CMA, exhibited increased airway inflammation and 
higher bronchial responsiveness to histamine at 8 years of 
age.
34,35 It is unclear whether the progression from IgE-mediat-
ed food allergy to asthma in subjects without eczema is causal 
or a result of shared environment and/or shared genetics. Be-
cause eczema and food allergy can co-exist in infants, hence, 
also unclear whether the observed association is related to co-
manifestation of other allergic conditions such as eczema and 
allergic rhinitis that predict asthma or is a consequence of CMA 
itself. It is important to have large population-based prospec-
tive cohorts to include food allergy as a baseline outcome to 
further investigate whether food allergy truly represents an ini-
tial step of the atopic march in infants with shared environmen-
tal and genetic determinants or whether it is an independent 
predictor.
ANIMAL MODELS SUPPORTING THE ATOPIC MARCH
Environmental and genetic studies provide evidence that a 
defect in epithelial barrier integrity may contribute to the onset 
of AD and progression of the atopic march. Many studies in an-
imal models demonstrate that epidermal barrier dysfunction 
can be caused by repeated sensitization to allergens to the skin, 
which leads to phenotypes of AD and systemic sensitization and 
increased risk of allergic rhinitis and lung inflammation and air-
way hyperresponsiveness.
36,37 A study in a mouse model showed 
that epicutaneous aeroallergen exposure induces systemic Th2 
immunity that predisposes to allergic nasal responses, suggest-
ing that the skin is a potent site for antigen sensitization in the 
development of experimental allergic rhinitis.
38 In addition, the 
progression from AD to asthma in mice is supported by the data 
that epicutaneous sensitization with ovalbumin induces local-
ized AD and airway hyperresponsiveness to methacholine after 
challenge with aerosolized ovalbumin.
36 In deed, murine mod-
els have shown that epicutaneous exposure to ovalbumin and 
peanut after the removal of the stratum corneum induces a 
strong systemic Th2 immune responses characterized by ele-
vated IL-4 secretion by T cells from draining lymph nodes and 
high levels of allergen specific IgE and IgG1.
33,39 Thymic stromal 
lymphopoietin (TSLP) in the pathogenesis in human AD has 
been well documented, and TSLP is shown to be highly in-
creased in human AD skin as well as in the blood of patients 
with AD.
40,41 However, its role in the atopic march in humans re-
mains to be defined. We and other show that the expression of 
TSLP is strongly increased by keratinocytes of AD skin in IL-13 
transgenic mouse of AD by IHC and ELISA
42 and that topical 
application of vitamin D3 induces TSLP expression in mouse 
keratinocytes and triggers AD.
43 TSLP, when overexpressed by 
skin keratinocytes, is a systemic driver of bronchial hyperre-
sponsiveness and its deletion prevents the atopic march from 
occurring suggesting that keratinocyte-produced TSLP may be 
involved in the link of AD to asthma.
44 A possible role of IL-17 in 
the atopic march is supported by a recent study showing that 
ovalbumin inhalation by epicutaneously-sensitized mice in-
duced expression of IL-17 and bronchial hyperreactivity, which 
are reversed by IL-17 blockade.
37
POTENTIAL MECHANISMS AND SPECULATIONS 
UNDERLYING THE ATOPIC MARCH
Previous approaches to understanding AD have centered on 
mechanisms in the adaptive immune system, often with an 
emphasis on the Th1–Th2 paradigm. Recently, the conceptual 
focus has increasingly shifted to including a primary defect in 
the epithelial barrier as a threshold event in AD. The epidermis 
provides an essential attribute to the integrity of occlusive inter-
face barrier, restricting both water loss from the body and in-
gress of pathogens. This barrier is formed after complex and in-
tegrated biochemical events. Epithelial keratinocytes replace 
their plasma membrane with a tough, insoluble layer termed 
the cornified envelope to achieve and maintain this barrier to 
prevent infectious agents and allergens from gaining access to 
the body. Although it has become evident that the mechanisms 
by which allergen exposure through the impaired skin barriers 
can initiate systemic allergy and predispose individuals to AD, Zheng et al.
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allergic rhinitis, and asthma, the cause of AD remains incom-
pletely understood, and the mechanisms of the atopic march is 
largely unknown.
SKIN BARRIER DEFECTS IN AD AND THE ATOPIC MARCH
The epidermis functions as a primary defense and biosensor 
to the external environment. Skin barrier defect promotes easy 
entry for pathogens, and allergens and other environmental in-
sults (toxins, irritants, pollutants) and is now considered as a 
primary mechanism of development of AD.
45 The skin barrier 
function is impaired in AD as a consequence of multiple abnor-
malities responsible for the barrier defect including reduced 
lipids (ceramide and sphingosine), abnormal keratinization due 
to dysfunctional filaggrin, a critical component in the cornified 
envelope formation.
22,46-50 Clinically the disrupted skin barrier is 
supported by the increased transepidermal water loss (TEWL) 
observed in both lesional and nonlesional skin.
45,51,52 Increased 
TEWL correlates with increased AD severity.
53 AD keratinocytes 
have an aberrant response to environmental triggers and are 
able to produce a unique profile of cytokines including IL-13, 
TSLP, and chemokines that promote Th2 predominant inflam-
matory responses in acute AD lesions followed by chronic AD 
characterized by prominent Th1 inflammation.
54 The mecha-
nism of the switch from Th2 inflammation in acute AD to Th1 
inflammation in chronic AD is not well understood. In addi-
tion, the impaired skin barrier can be further compromised by 
chronic heavy colonization of Staphylococcus aureus, which oc-
curs in 90% of AD patients.
55 Superantigens secreted from S. au-
reus in AD skin further stimulate keratinocytes to produce TSLP 
and induces polyclonal activation of T cells via binding directly 
to the common variable β (vβ) chains of T-cell receptors,
56-58 
which results in exaggerated Th2 inflammatory responses lead-
ing to worsening AD and may promote systemic Th2 responses 
and respiratory allergy. When allergens are captured and pro-
cessed by the Langerhans cells, the antigen-presenting cells of 
the epidermis, they migrate to draining lymph nodes and inter-
act with naïve T cells to promote Th2 immunity leading to sys-
temic allergies.
46
ROLE OF FILAGGRIN MUTATION IN AD AND IN THE 
ATOPIC MARCH
Many of the key structural proteins in the outermost layer of 
the epidermis involved in cornification are encoded for in a lo-
cus on chromosome 1q21, which is termed the epidermal dif-
ferentiation complex (EDC).
59 Genes found within this locus 
encode for filaggrin, a key member of the EDC, in addition to 
other proteins such as loricrin, involucrin, small proline-rich 
proteins, late envelope proteins, and the S100 calcium-binding 
proteins. Discovery of both independent loss-of-function ge-
netic variants (R510X and 2282del4) in the gene encoding filag-
grin, whose product is a key structural protein in the outermost 
layer of the epidermis in up to 50% of patients with AD, provides 
a genetic basis for the skin barrier defect in AD.
60 These recent 
genetic studies lend strong support to the role of filaggrin in the 
pathogenesis of AD and in the subsequent progression in the 
atopic march.
61 The filaggrin mutations are currently consid-
ered as a major risk factor for AD, particularly in patients who 
have onset of AD at 2 years or younger.
62 A recent study showed 
a significant association of two filaggrin gene mutations with 
asthma and allergic rhinitis, but this association is only seen in 
subjects with the co-existence of AD and the association is not 
apparent without the co-existence of AD.
48 In addition, filaggrin 
has currently not been found to be expressed in the human 
bronchial epithelium
63,64; hence, filaggrin mutations appear not 
to exert effects in the upper airway suggesting that the associa-
tion of filaggrin mutations with other atopic disorders is likely 
due to the common feature of allergen sensitization through 
the skin. Moreover, the fact that asthma is found only in a sub-
set of filaggrin mutation carriers with AD supports the hypoth-
eses that asthma is secondary to allergic sensitization that oc-
curs after epidermal skin barrier impairment. Filaggrin muta-
tions seem likely to play a role in chronicity of the disease and 
IgE sensitization in patients with AD. Recent studies show that 
patients with early-onset AD and filaggrin mutations have a 
tendency to have persistent disease into adulthood.
65 AD pa-
tients carrying filaggrin mutations are significantly associated 
with the extrinsic form of the disease (IgE-mediated sensitiza-
tion to inhalant or food allergens), and the development of al-
lergic rhinitis and asthma.
61,66,67 The filaggrin mutations predis-
posing to asthma, allergic rhinitis, and allergic sensitization 
only in the presence of AD strongly support the role of filaggrin 
in the pathogenesis of AD and in the subsequent progression 
along the atopic march. Expression of filaggrin gene is down-
regulated in AD skin by Th2 cytokines (IL-4 and IL-13)
68 and 
normal human keratinocytes by sphingosylphosphorylcholine, 
a proinflammatory and proprurigenic in AD
69,70 suggesting that 
filaggrin defects can develop as an acquired and/or genetic de-
fect. Reduced expression of loricrin and involucrin, two corni-
fied-envelope proteins, have been shown in the lesional skin of 
AD patients, which contributes to the skin barrier defects in 
AD
71,72 and their expression were also down-regulated by Th2 
cytokines.
73
Experimental evidence for the hypothesis that antigens enter 
through an impaired epidermal barrier inducing systemic al-
lergen-specific IgE responses is supported in mouse with filag-
grin frameshift mutation, analogous to human filaggrin muta-
tion. Epicutaneous application of allergen to these mice result-
ed in cutaneous inflammatory infiltrates and enhanced cuta-
neous allergen priming with development of IgE antibody re-
sponses.
74 Although genetic studies on filaggrin mutation indi-
cates that defective barrier function plays an initial key role in 
the pathogenesis of AD in many patients, much is still unknown Atopic Dermatitis: First Step in the Atopic March AAIR 
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about the sequence of biologic and regulatory events that con-
stitute the transition from an inherited barrier defect to clinical 
manifestations of eczematous dermatitis and susceptibility to 
related atopic disorders. The filaggrin gene mutation leads to an 
epithelial barrier defect and reduced mechanic defense mech-
anisms that allows easy entry for pathogens, allergens and oth-
er environmental insults (toxins, irritants, pollutants) followed 
by polarized Th2 lymphocyte responses with resultant chronic 
inflammation. However, approximately 40% of carriers of filag-
grin gene mutations do not develop AD.
75 Patients with ichthy-
osis vulgaris, an inherited dry, scaly skin disorder who have fil-
aggrin mutations
76 do not have apparent skin inflammation or 
infection, which are cardinal features of human AD. Therefore, 
additional factors may directly and or indirectly interact with 
filaggrin in the pathogenesis of AD.
CONCLUSION
Multiple lines of evidence (clinical, genetic and experimental 
studies) suggest that previous expression of AD is a prerequisite 
for the development of allergic rhinitis and asthma and specific 
sensitization highlighting the importance of the epidermal bar-
rier in the pathogenesis of these disorders. Whether AD in the 
march is necessary for progression to other atopic disorders re-
mains to be defined. To establish a causal relationship from AD 
to airway allergic diseases, evidence of immunological mecha-
nisms accounting for the association and randomized controlled 
trials demonstrating an effective intervention for AD with re-
duced subsequent asthma incidence are necessitated. It also is 
important to identify infants at risk for developing lifelong chron-
ic atopic diseases to provide a critical window of opportunity 
early in life for therapeutic intervention. Therapy targeting the 
maintenance and repair of the epidermal barrier in infants with 
AD may prevent the subsequent development of asthma.
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